Detalles de la búsqueda
1.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Ann Rheum Dis
; 78(10): 1305-1319, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350269
2.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Ann Rheum Dis
; 78(10): 1320-1332, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350270
3.
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis Res Ther
; 22(1): 47, 2020 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164762
4.
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis Res Ther
; 22(1): 155, 2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32576246
5.
Phenytoin stimulates chondrogenic differentiation in mouse clonal chondrogenic EC cells, ATDC5.
J Toxicol Sci
; 30(3): 145-56, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16141649
Resultados
1 -
5
de 5
1
Próxima >
>>